Martinez-Trufero, JavierDe-Sande-Gonzalez, Luis MiguelLuna, PabloMartin-Broto, JavierAlvarez, RosaMarquina, GloriaDiaz-Beveridge, RobertoPoveda, AndresCano, Juana MariaCruz-Jurado, JosefinaLopez-Pousa, AntonioVaz-Salgado, Maria AngelesValverde-Morales, Claudia M.Sevilla, IsabelMartinez-Garcia, JeronimoRubio-Casadevall, JordiDe Juan, AnaCarrasco, Juan AntonioMoura, David S.Gurruchaga-Sotes, IbonGutiérrez, Antonio2022-12-142022-12-142021-02-14Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, et al. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers. 2021 Feb 14;13(4):792http://hdl.handle.net/10668/4498The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.enAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/TrabectedinSarcomaGrowth modulation indexPrognostic scoreL-sarcomaGEISTRASpainAdvanced soft tissue sarcomasTrabectedinaPronósticoLiposarcomaLeiomiosarcomaEspañaMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::PrognosisMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective StudiesMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiazoles::Thiamine::Thiamine TriphosphateMedical Subject Headings::Geographical Locations::Geographic Locations::Europe::SpainMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::SarcomaMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate AnalysisMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::LeiomyosarcomaMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma::Liposarcomaresearch article33672857open access10.3390/cancers130407922072-6694PMC7917652